Avidity Biosciences

25 articles with Avidity Biosciences

• Avidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020

  9/28/2020

  - Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, Arthur Levin , Ph.D., Chief Scientific Officer, and Mike MacLean , Chi

• Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings

  9/14/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will present at several upcoming virtual scientific meetings.

• Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1

  9/8/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced it entered into a collaboration supporting END-DM1, a natural history study to advance the understanding of disease progression in patients w

• Avidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference

  9/3/2020

   Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , Avidity's President and CEO, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference

• Avidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

  8/10/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter and six months ended June 30, 2020 and highlighted recent corporate progress.  

• Avidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer

  7/27/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Jae Kim , M.D. as Chief Medical Officer.  In his new role, Dr. Kim will be responsible for leading and expanding Avidity's AOC

• Avidity Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

  6/16/2020

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the closing of its initial public offering of 16,560,000 shares of common stock,

• 

  Biopharma Companies Seek Hundreds of Millions in June IPOs

  6/15/2020

  BioSpace takes a look at some of the most recent IPO plans from companies across the globe.

• Avidity Biosciences Announces Pricing of Initial Public Offering

  6/11/2020

  Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of 14,400,000 shares of common stock at a public offering price of $18.00 per share.

• Avidity Biosciences Appoints Michael MacLean as Chief Financial Officer

  5/19/2020

  Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Michael MacLean as Chief Financial Officer. 

• Avidity Biosciences Appoints Carsten Boess to its Board of Directors

  4/13/2020

   Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Carsten Boess to its board of directors.  Mr. Boess, who has nearly thirty years of industry experience as a finance executive and board member, brings a wealth of experien

• Avidity Biosciences Announces Presentations at Upcoming Investor Conferences

  2/24/2020

  SAN DIEGO , Feb. 24, 2020 /PRNewswire/ --   Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today that Sarah Boyce , Avidity's President and CEO, will present a company overview at two upcoming investor conferences: 9 th Annual SVB Leerink Global

• Avidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer

  2/12/2020

  SAN DIEGO , Feb. 12, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Joseph Baroldi as Chief Operating Officer.  "We are thrilled to welcome Joe to the Avidity team," said Sarah Boyce , Preside

• 

  JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation

  1/13/2020

  It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.

• Avidity Biosciences Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

  1/7/2020

  Avidity Biosciences announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 in San Francisco, CA.

• Avidity Biosciences Completes $100 Million Series C Financing

  11/13/2019

  Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 million Series C financing.

• Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer

  10/1/2019

  Avidity Biosciences announced the appointment of global business leader Sarah Boyce as President and Chief Executive Officer and a member of the Avidity Board of Directors.

• Avidity Biosciences to Present at the 2019 Myotonic Annual Conference

  9/12/2019

  Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D., Chief Scientific Officer, is scheduled to present at the 2019 Myotonic Annual Conference on Saturday, September 14 at 4:00 p.m. ET.

• 

  BioSpace Movers & Shakers, Aug. 23

  8/23/2019

  Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.

• Avidity Biosciences Adds Drug Development Veterans Edward Kaye and Noreen Henig to Board of Directors

  8/22/2019

  Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) focused in rare muscle disorders and other serious diseases, today announced the appointment of Noreen Henig, M.D., and Edward Kaye, M.D., to the company's board of directors.